Background and Aims: One of the adverse effects of the tumour necrosis factor alpha [[TNFα] monoclonal antibodies for the treatment of immune-mediated inflammatory diseases is a higher propensity for tuberculosis development. The aim of this study was to explore the utility and sensitivity of serial tuberculosis screening during anti-TNFα treatment. Methods: A cohort of 46 inflammatory bowel disease patients receiving infliximab was prospectively recruited and followed for 26 months. During this period of time, a tuberculosis skin test and two different interferon ϒ release assays [QFT-GIT and T-SPOT.TB] were applied at 4-6-month intervals. Results: Overall, 16 patients were diagnosed with latent tuberculosis infection after having at least one test conversion: 12 patients had a positive tuberculosis skin test, seven patients had a positive T-SPOT.TB, and two patients had a positive QFT-GIT. Active tuberculosis was excluded in all; 15 were treated with isoniazid. A comparison between tests showed a moderate accuracy [72% to 85%] but low kappa values [0.063 to 0.377]. Concerning association with demographic and clinical characteristics, test conversion was more common among the male gender and those with a longer disease duration. Conclusions: Tuberculosis tests conversions were common in inflammatory bowel disease patients treated with infliximab alone or in association with immunomodulators. In these immunosuppressed individuals, the classical tuberculosis skin test seems to have a higher sensitivity than the modern tests based on the release of interferonϒ.
Introduction
The introduction of tumour necrosis factor alpha monoclonal antibodies [anti-TNFα] into the therapeutic armamentarium against immune-mediated inflammatory diseases has improved the prognosis and health-related quality of life of patients afflicted with these diseases. However, anti-TNFα therapy is not exempt from risks, one of which is an increased propensity towards tuberculosis [TB] development. Among the different anti-TNFα drugs currently approved for the treatment of immune-mediated inflammatory diseases, infliximab and adalimumab pose the highest risk for TB development. 1, 2 Previous TB screening and adequate treatment upon evidence of a latent TB infection [LTBI] are crucial steps to prevent a TB reactivation during anti-TNFα therapy, 3 and are now standard care. These actions are known to reduce the TB incidence by up to 85% in persons treated with anti-TNFα. 4, 5 Nevertheless, TB cases still occur among anti-TNFα treated patients. 2 These cases might be explained by either failures in the previous LTBI diagnosis or treatment, or by incidental new infections. Concerning LTBI diagnosis failures, it is important to stress that LTBI tests are far from perfect: both the classical tuberculin skin test [TST] and the more specific Mycobacterium tuberculosis interferon-γ release assays [IGRAs] are known to have a suboptimal performance particularly among immunosuppressed individuals. [6] [7] [8] Moreover, LTBI treatment adherence may be poor, and new infections can occur, particularly in countries with intermediate or high TB incidence rates. 5, 9 Repeating the TB screening during the anti-TNFα therapy seems like a rational approach to minimising this issue. However, its utility and the best screening method [considering that the patients involved have been tested before] remain controversial. 5, 9, 10 The number of longitudinal studies assessing the performance of TB re-screening in patients receiving anti-TNFα therapies is rather limited, 8, 11 and both the interpretation of IGRA results and the criteria for LTBI treatment among individuals receiving anti-TNFα are yet to be established. 12 This study was designed to evaluate the usefulness of TB serial re-screening-using TST and two different IGRA tests-among a population of inflammatory bowel disease [IBD] patients on infliximab therapy. The main goals were: a] to detect the frequencies of IGRA conversions and reversions and evaluate their agreement with the TST results; and b] to evaluate whether and how TB rescreening may contribute to better and more accurate TB diagnosis and control. To do so, a population of inflammatory bowel disease [IBD] patients receiving infliximab was prospectively evaluated at defined time points to test the presence of LTBI, using three different methods-two IGRA tests (T-SPOT.TB and Quantiferon gold intube [QFT-GIT]) and the TST-for a follow-up time of 26 months.
Material and Methods

Cohort and study design
This study involved IBD patients being treated with infliximab and prospectively and consecutively recruited from the outpatient department of a community hospital in the northern region of Portugal during July-August 2013. As inclusion criteria, patients were required to be over 18 years old and to have a negative test for TB before starting the anti-TNFα therapy (ie a negative TST [boosted or not boosted] and a negative chest radiograph for TB, for patients starting anti-TNFα after 2011, a negative QFT-GIT test result). Patients with a previous TB positive screening and/or TB therapy and with a known contact with active tuberculosis patients were excluded from this analysis, as were women who were pregnant at recruitment. A few patients declined to participate as they were working abroad.
The patients' baseline assessment included a clinical interview, a chest radiograph, and two TB screening tests: a TST and an IGRA test, the T-SPOT.TB. These two tests were repeated after 4, 8, 14, 20, and 26 months. A second IGRA test, the QFT-GIT, was performed at the 4th, 8th, and 20th month of follow-up.
This study was approved by the hospital ethics committee and all patients gave written informed consent before participation.
Test application and interpretation
TST [Tuberculin PPD RT 23SSI, Statens Serum Institute] was performed according to the Mantoux method, and an induration ≥ 5 mm was considered to be positive. A TST conversion was described as an induration of ≥ 5 mm after an initial negative TST. IGRA tests [QFT-GIT] [Cellestis Limited, Carnegie, Victoria, Australia], and T-SPOT.TB [Oxford Immunotec, UK] were performed and interpreted according to the manufacturer's instructions by trained technicians who were blinded to the TST results. Briefly, and concerning the QFT-GIT test, the IFN-γ cut-off was 0.35 IU/mL, and each sample result was calculated by subtracting the negative control from the TB antigen-stimulated sample only and if the negative control was below 8.0 IU/mL. Whenever the IFN-γ response in the TB antigenstimulated sample was below 25% of the negative control, the result was considered to be negative irrespective of its relation to the cutoff. Test results with a negative control over 8.0 IU/mL or a positive control less than 0.5 IU/mL were considered to be indeterminate. Concerning the T-SPOT.TB tests, the results were interpreted by subtracting the spot-forming cells [SFCs] count in the negative control from that of the sample stimulated by the ESAT-6 and CFP-10 antigens. Samples were considered to be positive when ESAT-6 or CFP-10 stimulated wells had at least six spots over the number of spots found in the negative control, whenever the negative control had 10 spots or fewer. If the negative control well had more than 10 spots and/or there were less than 20 spots in the mitogen positive control wells, the result was considered to be indeterminate, according to the explicit criteria in the manufacturer's version 1 [TG-TB-UK-V1].
Diagnosis criteria
LTBI was diagnosed upon the conversion of at least one of the TB tests in the absence of clinical, radiological, and microbiological evidence of disease. Patients diagnosed with LTBI were treated with isoniazid, according to the usual proceedure. Moreover, and to rule out the possibility of active TB, these patients were subjected to a clinical interview, a chest radiograph, thorax computed tomography [CT] , and, whenever possible, sputum was collected and examined to assess the presence of Mycobacterium spp.
Statistical analysis
Categorical variables were described through absolute and relative frequencies, and continuous variables were described as mean and standard deviation, median, percentiles, minimum, and maximum. The concordance between the three tests was analysed using the Cohen's kappa coefficient: kappa values > 0.75 were considered to represent excellent agreement beyond chance; values 0.40-0.75 were considered to represent fair to good agreement beyond chance; and values < 0.40 were considered to represent poor agreement beyond chance. All the reported p-values were two-sided, and p-values of < 0.05 were considered statistically significant. All data were arranged, processed, and analysed with SPSS ® v.23.0 data [Statistical Package for Social Sciences].
Results
Cohort characterisation
A total of 48 Portuguese patients from similar residence were initially enrolled in the study, but two were later excluded: one was lost to follow-up after the second screening, and the other was found to have been treated for LTBI before. From the 46 patients that composed the final cohort [ [MTX] , or steroids combined with AZA or MTX). Patients' median age was 38 years, and they had been diagnosed a median of 8.5 years before enrolment in this study. Fifteen patients were on infliximab for less than 1 year, 16 were on infliximab for 1-3 years, and 15 had had more than 3 years of infliximab therapy. In accordance with the Portuguese National Vaccination Plan, all patients were BCG-vaccinated at birth; for a few of them, this vaccine was repeated during childhood.
Test results
Overall, 649 TB screening tests were performed: 276 were T-SPOT. TB, 138 were QFT-GIT, and 235 were TST. Of those, 32 [ Concerning the evolution of IGRA test results, two of the patients who tested positive with T.SPOT.TB maintained a positive [or borderline] response to this test in the following screenings. Regarding QFT-GIT, the patient who tested positive at the 4th month had another positive result at the 20th month, although a negative response was reported at the 8th month. TSTs were not repeated after displaying an induration of 10 mm or more, in accordance to the tuberculin administration guidelines.
13 Table 1 shows a comparison of the patients diagnosed with LTBI with those in whom TB screening tests remained negative along the entire follow-up: the former had a significantly higher percentage of male patients as well as a longer IBD evolution [10.6 vs 6 years].
Clinical evaluation and follow-up of LTBIdiagnosed patients
The 16 patients diagnosed with LTBI after a TB screening test conversion were immediately evaluated: all of them were asymptomatic and, to their knowledge, had no contact with an active TB patient. The chest X-ray and thorax CT did not reveal lesions. Therefore, all these patients were maintained on infliximab. Concerning LTBI therapy, 15 patients were started on isoniazid and pyridoxine for a predicted period of 9 months.
14,15 Patient number 2 [ Table 2 ] had a single positive test result [six SFCs in the T-SPOT.TB] and was asymptomatic, and was excluded from the LTBI treatment. Fourteen patients completed the 9 months on isoniazid without any remarkable clinical or analytical intolerance; a single patient interrupted the prophylactic therapy after 4 months due to gastrointestinal intolerance. No case of active TB was reported among the 46 included patients during the entire follow-up period.
Discussion
Anti-TNFα associated TB cannot be fully prevented by TB screening before treatment. 16 At the present time, the best procedure to tackle this issue remains unknown. In this study, 46 adult IBD patients on infliximab were followed for 26 months, during which the classical TST and two different IGRAs were serially applied. The first three screening points were done at 4-month intervals, whereas the latter three were done at 6-month intervals.
Remarkably, 16 [34.5%] of these patients had at least one positive TB screening test result during the 26 months of the follow-up. It should be noticed that, besides infliximab, most patients [72%] were on concomitant therapies [steroids and immunomodulatory drugs] known to affect the TB screening tests' performance. 8 In most cases [12] , the initial test conversion included a positive TST, whereas only seven and two were positive for TSPOT.TB and QFT-GIT, respectively. These results are similar to those reported by Hatzara et al., who described 29% TB test conversions in a population of 70 patients with rheumatic diseases, after 12 months of anti-TNFα therapy. 17 Moreover, these authors also reported that positive results were more frequently found among TST than among IGRA tests. In this study, the differences between the test results are perceptible in the low kappa values and moderate accuracies found upon comparing them.
Patients diagnosed with LTBI were more frequently male and had had IBD for a longer time than those whose TB screening tests remained negative throughout the follow-up. We wonder if IBD stability after a long medication period could somehow rescue part of the immune function, contributing to LTBI test conversion. 18 The reasons for the higher conversion ratio among men are also not entirely clear. However, the results reported here are similar to those published by Cuomo et al., who found that male gender was associated with a higher risk of TB conversion in an Italian cohort of patients with rheumatoid arthritis. 19 Interestingly, women are known to be prone to a deeper immunossupression-related to physiological aspects of pregnancy-and anergy to delayed hypersensitivity reactions is more commonly observed among women than men. 20 The classical TST has been pointed out as limited in some aspects. One of these is the so-called boosting effect potentially elicited by repeated TSTs: according to this effect, the number of positive TSTs should increase with the number of repetitions and therefore over time [in this study]. However, 11 out of the 12 TST conversions occurred in the initial 8 months of the study, and a single conversion occurred in the following 15 months. It should also be noticed that patient number 7 had a 6-mm induration at the 4th month, being therefore a good candidate for a 'boosted' effect. However, all his following TSTs were negative. Accordingly, several studies agree that a boosting effect is uncommon when more than 2 months have elapsed between tests, 21 and this study involved TST repetitions with 4-6 months of interval between them.
Another potential limitation of the TST is the fact that false-positives may occur among patients whom have been vaccinated with BGC at birth, such as the patients enrolled in this cohort. However, it should be noticed that all patients had at least one negative TST before being placed on anti-TNFα therapy. Moreover, it has been argued that the effect of the BCG vaccination on the positivity of TST in adults aged more than 30 years is negligible, 22 and eight of the 12 patients who had a positive TST in this study were indeed over 30. In fact, the 2016 National Institute for Health and Care Excellence [NICE] tuberculosis guidelines stated that, according to 14 different studies exploring the association between test positivity and BCG, there was no strong evidence of an association between BCG vaccination history and TST positivity, indicating that the impact of BGC vaccination on test positivity could be similar for IGRA and TST. 23 Finally, TST is not as specific as IGRA, and may have positive results following infections with atypical Mycobacteria spp. Still, this effect seems to be irrelevant in non-tropical areas, 13, 24 which is the case in the study reported here. One should also consider the possibility that TST, which includes TB antigens that are present on the IGRA tests, leads to false-positive results in the latter due to yet another boosting effect. This question was addressed in a previous systematic review that suggested that the boosted effect seen when the QFT-GIT was performed over 3 months after TST administration waned, although further studies are required to validate this conclusion. 25 As to T-SPOT.TB, a large IGRA tests are more recent and have a few advantages over the TST-namely specificity-for the LTBI diagnosis in the general population. However, and when considering immunosuppressed individuals, the picture is not as clear. 27 In fact, anti-TNF therapies reduce the production of inflammatory cytokines such as interferongamma [IFN-γ], interleukin-1, and TNF-α from T lymphocytes. 28 As the IGRA tests are precisely based on the quantification of the IFN-γ released after ESAT-6, CFP-10, and TB7.7 stimulation, the inhibition of IFN-γ production in anti-TNFα treated individuals may yield false-negative and indeterminate results. In fact, a metaanalysis published by Wong et al. has shown a markedly negative impact of steroids, oral immunomodulatory drugs, and biological therapies on IGRA results. 29 This effect was apparently more relevant for the QFT-GIT than for the T-SPOT.TB. In this study, the number of positive results obtained with the latter was 3-fold higher than that obtained with the former [7vs 2]. Still, QFT-GIT was performed in only three out of the six screening time points, which may have introduced some bias in the results. Nevertheless, the low number of positives obtained with the IGRA tests when compared with the TSTs, together with the borderline and indeterminate results, support the idea that IGRA tests alone may not be the best choice to monitor TB in immunosuppressed individuals. It remains to be determined whether the use of different cut-offs could improve these tests' performance in this specific population.
The analysis of the evolution of the IGRA test results after starting isoniazid therapy was limited by the small number of positive tests. Whereas positivity was maintained in a few patients, others reverted to negative test results, and no clear pattern could be established. Interestingly, in another recent study, the authors failed to find the expected decrease in IFN production upon LTBI antibiotic therapy. 30 One important limitation of this study is the fact that one cannot compare its results with the general population, as there are no similar studies performed in the latter. In fact, the only healthy population group on whom serial testing of tuberculosis is performed are health care workers [HCWs] , who have a high risk of tuberculosis. One manuscript published in 2011, with data from HCWs working in our hospital, found a conversion rate of 30. 7% for a second TST [increase of > 10 mm] and 11% for a second QFT test in a cohort of 670 HCWs [data were collected during 2007 to 2009]. 31 Moreover, a third QFT test presented a conversion rate of 6.6%. However, the authors state that, at that time, the annual incidence of active tuberculosis in HCWs [192 per 100 000] was about six times higher than that in the general population in Portugal, so one can hardly extrapolate these results and compare the risk of HCWs with the risk of anti-TNF prescription.
Briefly, this study revealed a remarkably high number of positive TB results among a population of IBD patients being treated with infliximab with or without concomitant immunomodulatory drugs and steroids. TST had the highest ratio of positive results, followed by T-SPOT.TB and QFT-GIT: overall, test results were non-concordant. Male patients and those who had a longer disease evolution were more prone to test conversions. This suggests that re-testing should be tailored and focused on those more likely to develop TB. Still, the optimal timing and sensitivity of these re-testing procedures, as well as the most suitable IGRA test and respective cut-off for immunosuppressed patients, and how to validate the reversions and conversions of the test results, are to be determined: larger, prospective, long-term studies are needed in order to do so. Meanwhile, and given the low ratio of positive results obtained from IGRA tests in the setting of re-testing for TB, TST should likely be maintained as it offers a more high-sensitivity strategy that minimises false-negatives.
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